FindTrial
Sign In

ETC-1002

DRUG10 trials

Sponsors

Esperion Therapeutics, Inc.

Conditions

Atherosclerotic Cardiovascular DiseasesDyslipidemiaHypercholesterolemiaHyperlipidemiaHypertensionSafety Evaluation of Escalating DosesType 2 Diabetes

Phase 1

A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects
CompletedNCT01485146
Esperion Therapeutics, Inc.Safety Evaluation of Escalating Doses
Start: 2011-10-25End: 2012-01-25Updated: 2019-03-28

Phase 2

A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
CompletedNCT01262638
Esperion Therapeutics, Inc.Dyslipidemia
Start: 2010-12-31End: 2011-08-23Updated: 2021-03-17
A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes
CompletedNCT01607294
Esperion Therapeutics, Inc.Hyperlipidemia, Type 2 Diabetes
Start: 2012-04-30End: 2012-10-31Updated: 2019-03-29
A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance
CompletedNCT01751984
Esperion Therapeutics, Inc.Hypercholesterolemia
Start: 2012-10-04End: 2013-05-01Updated: 2022-04-04
A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia
CompletedNCT01779453
Esperion Therapeutics, Inc.Hypercholesterolemia
Start: 2012-12-31End: 2013-08-31Updated: 2019-03-29
Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
CompletedNCT01941836
Esperion Therapeutics, Inc.Hypercholesterolemia
Start: 2013-09-30End: 2014-11-30Updated: 2019-03-29
Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy
CompletedNCT02072161
Esperion Therapeutics, Inc.Hypercholesterolemia
Start: 2014-03-31End: 2015-01-31Updated: 2019-03-29
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
CompletedNCT02178098
Esperion Therapeutics, Inc.Hypercholesterolemia, Hypertension
Start: 2014-06-16End: 2015-05-22Updated: 2023-04-04
A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg
CompletedNCT02659397
Esperion Therapeutics, Inc.Hyperlipidemia
Start: 2015-12-31End: 2016-07-31Updated: 2019-03-29

Phase 3

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)
CompletedNCT02666664
Esperion Therapeutics, Inc.Atherosclerotic Cardiovascular Diseases, Hypercholesterolemia
Start: 2016-01-21End: 2018-03-28Updated: 2020-05-11

Related Papers

Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial.
2023-02-1443 citations
Factors Associated With Enhanced Low‐Density Lipoprotein Cholesterol Lowering With Bempedoic Acid
Journal of the American Heart Association2022-08-0215 citations
Long-term safety and efficacy of bempedoic acid in patients at high risk of atherosclerotic cardiovascular disease: results from the CLEAR Harmony open-label extension study
European Heart Journal2020-11-017 citations
Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia
JAMA Cardiology2020-07-01178 citations
Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial.
2019-05-1340 citations
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
New England Journal of Medicine2019-03-13756 citations
Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy
The American Journal of Cardiology2016-04-06124 citations
Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance
Journal of clinical lipidology2016-01-06144 citations
Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
2013-06-13118 citations